Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.
Type:
Grant
Filed:
July 18, 2011
Date of Patent:
June 10, 2014
Assignee:
Mati Therapeutics Inc.
Inventors:
Eugene De Juan, Jr., Stephen Boyd, Cary Reich, Alan Rapacki, Hanson S. Gifford, Mark Deem
Abstract: The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s).
Abstract: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.
Type:
Grant
Filed:
August 29, 2012
Date of Patent:
April 22, 2014
Assignee:
Mati Therapeutics, Inc.
Inventors:
Alan R. Rapacki, Valery Rubinchik, John B. Holds, Sylvie Sim, Danny Shen
Abstract: A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.
Type:
Grant
Filed:
October 4, 2012
Date of Patent:
April 8, 2014
Assignee:
Mati Therapeutics, Inc.
Inventors:
Eugene de Juan, Jr., Stephen Boyd, Hanson S. Gifford, III, Mark Deem, Cary J. Reich
Abstract: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.
Type:
Grant
Filed:
February 7, 2012
Date of Patent:
January 14, 2014
Assignee:
Mati Therapeutics, Inc.
Inventors:
Deepank Utkhede, Robert W. Shimizu, Rachna Jain, Stephen Boyd, Hanson S. Gifford, Eugene De Juan, Jr., Cary J. Reich